Other Voices: Why Fate Therapeutics Could Continue To Move Higher

By Ian Copper

Earlier this week, shares of Fate Therapeutics (FATE) closed at $20.41, flat from the prior trading day. The biotech stock is up nearly 74% from a low of $11.70 set in January 2019. That’s more than triple the return of the iShares NASDAQ Biotechnology ETF (IBB), and the S&P 500’s gain of 27% on the year. Wall Street is looking for further strength from the company, given its strong pipeline of drug treatments.

Comments


Bret Jensen
EditorBret Jensen
alexandra
Editoralexandra
New Comment
1
Bret Jensen
EditorBret Jensen
New Comment
allisondbl
1
Bret Jensen
EditorBret Jensen
New Comment
fadiwd
Bret Jensen
EditorBret Jensen
New Comment
Timothy Blackbread
alexandra
Editoralexandra
New Comment
Bret Jensen
EditorBret Jensen
New Comment
altheqa
Bret Jensen
EditorBret Jensen
New Comment
Bret Jensen
EditorBret Jensen
New Comment